Altimmune

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.

CEO

Vipin K. Garg

CEOVipin K. Garg

Employees

Employees59

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1997

Founded1997

Employees

Employees59

ALT Key Statistics

Market cap

438.74M

Market cap438.74M

Price-Earnings ratio

-4.42

Price-Earnings ratio-4.42

Dividend yield

—

Dividend yield—

Average volume

3.81M

Average volume3.81M

High today

$6.09

High today$6.09

Low today

$5.45

Low today$5.45

Open price

$5.93

Open price$5.93

Volume

2.80M

Volume2.80M

52 Week high

$11.16

52 Week high$11.16

52 Week low

$5.14

52 Week low$5.14

ALT News

Seeking Alpha 3d

Altimmune rises as buyout rumors follow R&D updates

Shares of Altimmune (NASDAQ:ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors on Wall Street a day after issuing not...

TipRanks 3d

Altimmune call volume above normal and directionally bullish

Bullish option flow detected in Altimmune (ALT) with 13,503 calls trading, 4x expected, and implied vol increasing over 44 points to 140.99%. Mar-25 6 calls and...

TipRanks 3d

Evercore bullish on Altimmune, likes drug move into alcohol related disease

Evercore ISI likes the expansion of pemvidutide into alcohol liver disease and alcohol use disorder as it adds another leg to the pemvidutide story and one that...

Analyst ratings

80%

of 10 ratings

Buy

80%

Hold

20%

Sell

More ALT News

TipRanks 3d

Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $25.00. Jonathan Wolleben...